Literature DB >> 17599318

Improving survival among HIV-infected injection drug users: how should we define success?

Gregory D Kirk, David Vlahov.   

Abstract

Entities:  

Mesh：

Year:  2007        PMID： 17599318      PMCID： PMC4078728          DOI： 10.1086/519426

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  27 in total

1.  Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis. Collaborative Group on AIDS Incubation and HIV Survival including the CASCADE EU Concerted Action. Concerted Action on SeroConversion to AIDS and Death in Europe.

Authors: 
Journal:  Lancet       Date:  2000-04-01       Impact factor: 79.321

2.  A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival.

Authors:  A Mocroft; S Madge; A M Johnson; A Lazzarin; N Clumeck; F D Goebel; J P Viard; J Gatell; A Blaxhult; J D Lundgren
Journal:  J Acquir Immune Defic Syndr       Date:  1999-12-01       Impact factor: 3.731

3.  Uniform risk of clinical progression despite differences in utilization of highly active antiretroviral therapy: Swiss HIV Cohort Study.

Authors:  C Junghans; N Low; P Chan; A Witschi; P Vernazza; M Egger
Journal:  AIDS       Date:  1999-12-24       Impact factor: 4.177

4.  Pre-AIDS mortality and its association with HIV disease progression in haemophilic men, injecting drug users and homosexual men.

Authors:  M Prins; C A Sabin; C A Lee; H Devereux; R A Coutinho
Journal:  AIDS       Date:  2000-08-18       Impact factor: 4.177

5.  Effect of hard-drug use on CD4 cell percentage, HIV RNA level, and progression to AIDS-defining class C events among HIV-infected women.

Authors:  Lorna E Thorpe; Margaret Frederick; Jane Pitt; Irene Cheng; D Heather Watts; Shelley Buschur; Karen Green; Carmen Zorrilla; Sheldon H Landesman; Ronald C Hershow
Journal:  J Acquir Immune Defic Syndr       Date:  2004-11-01       Impact factor: 3.731

6.  Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.

Authors:  Cunlin Wang; David Vlahov; Noya Galai; Joseph Bareta; Steffanie A Strathdee; Kenrad E Nelson; Timothy R Sterling
Journal:  J Infect Dis       Date:  2004-08-17       Impact factor: 5.226

7.  Evaluation of possible effects of continued drug use on HIV progression among women.

Authors:  Anne M Rompalo; Nina Shah; Joseph B Margolick; Homayoon Farzadegan; Julia Arnsten; Paula Schuman; Josiah D Rich; Lytt I Gardner; Dawn K Smith; David Vlahov
Journal:  Int J STD AIDS       Date:  2004-05       Impact factor: 1.359

8.  Mortality of intravenous drug users in Rome: a cohort study.

Authors:  C A Perucci; M Davoli; E Rapiti; D D Abeni; F Forastiere
Journal:  Am J Public Health       Date:  1991-10       Impact factor: 9.308

9.  Determinants of survival following HIV-1 seroconversion after the introduction of HAART.

Authors:  Kholoud Porter; Abdel Babiker; Krishnan Bhaskaran; Janet Darbyshire; Patrizio Pezzotti; Kholoud Porter; A Sarah Walker
Journal:  Lancet       Date:  2003-10-18       Impact factor: 79.321

10.  How well do clinicians estimate patients' adherence to combination antiretroviral therapy?

Authors:  Loren G Miller; Honghu Liu; Ron D Hays; Carol E Golin; C Keith Beck; Steven M Asch; Yingying Ma; Andrew H Kaplan; Neil S Wenger
Journal:  J Gen Intern Med       Date:  2002-01       Impact factor: 5.128
View more
  5 in total

1.  Response to: The relationship of physical performance with HIV disease and mortality: a cohort study.

Authors:  Daisson José Trevisol; Alexandre Da Silva; Clávison Martinelli Zapelini; Fabiana Schuelter-Trevisol; Fabricio De Souza
Journal:  AIDS       Date:  2015-03-27       Impact factor: 4.177

2.  The relationship of physical performance with HIV disease and mortality.

Authors:  Meredith Greene; Kenneth Covinsky; Jacquie Astemborski; Damani A Piggott; Todd Brown; Sean Leng; Noya Galai; Shruti H Mehta; Jack Guralnik; Kushang V Patel; Gregory D Kirk
Journal:  AIDS       Date:  2014-11-28       Impact factor: 4.177

3.  Nonstructured treatment interruptions among injection drug users in Baltimore, MD.

Authors:  Ravi Kavasery; Noya Galai; Jacquie Astemborski; Gregory M Lucas; David D Celentano; Gregory D Kirk; Shruti H Mehta
Journal:  J Acquir Immune Defic Syndr       Date:  2009-04-01       Impact factor: 3.731

4.  Differential survival benefit of universal HAART access in Brazil: a nation-wide comparison of injecting drug users versus men who have sex with men.

Authors:  Monica Malta; Francisco I Bastos; Cosme M F P da Silva; Gerson Fernando Mendes Pereira; Francisca F A Lucena; Maria G P Fonseca; Steffanie A Strathdee
Journal:  J Acquir Immune Defic Syndr       Date:  2009-12       Impact factor: 3.731

5.  Provider and clinic-level correlates of deferring antiretroviral therapy for people who inject drugs: a survey of North American HIV providers.

Authors:  Ryan P Westergaard; Bridget K Ambrose; Shruti H Mehta; Gregory D Kirk
Journal:  J Int AIDS Soc       Date:  2012-02-23       Impact factor: 5.396
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.